• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Valeritas touts use of V-Go device compared to insulin injections

August 2, 2018 By Sarah Faulkner

Valeritas V-Go deviceValeritas (NSDQ:VLRX) touted data today from an analysis showing that insulin-dependent people with Type 2 diabetes benefited from using the company’s wearable V-Go insulin delivery device.

The study featured people who previously treated their diabetes using multiple daily injections of insulin. After switching to the V-Go device under the care of advanced practitioners, participants were monitored and evaluated at the three- and seventh-month mark.

After three months, researchers observed a mean change in A1c of -1.1% from the mean baseline of 9.1% and a mean total daily insulin dose of 58 units per day compared to a mean baseline of 87 units per day. After seven months, the mean change in A1c was -1.1% and the mean total daily insulin dose was 61 units per day, according to Valeritas.

“For many patients with Type 2 diabetes, being able to adhere to an insulin regimen consisting of multiple daily injections is a real challenge as it can be burdensome to daily living and complex,” Amanda Patricia Wakim, a nurse practitioner in Wheeling, West Virginia, said in prepared remarks.

“In my practice, V-Go has been well received by patients as it removes the need for multiple injections, is simple to use, and has enabled many of my patients to lower their glucose, use less insulin, and not gain the weight normally seen with intensified insulin therapy,” she added.

“Insulin only works if patients actually take it.  For many, that includes taking it around each meal and away from their home,” president & CEO John Timberlake said. “This data from patients using V-Go prescribed by Advanced Practitioners is consistent with previously published data showing how patients can lower their blood glucose and do so using less insulin.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Valeritas Inc.

IN CASE YOU MISSED IT

  • Tandem Diabetes Care delivers 1 million insulin boluses using t:connect mobile app
  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS